Talon Therapeutics (TLON) Inactive 10-Q2010 Q1 Quarterly report

Filed: 14 May 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: add, alliance, appointed, breast, choice, chromosome, colon, comprised, confirm, covered, CR, creating, CRi, delivered, diminished, dividend, final, finalize, focused, Food, foundation, head, hematological, human, impede, innovative, insufficient, intrinsic, main, median, neck, nonqualified, offset, pancreatic, partnership, Philadelphia, primary, proceed, proposed, purpose, recovery, remeasured, remission, reorganization, resale, rolling, run, stockholder, successful, survival, therapy, underlying, unused, viability, voting

Removed: adjustment, advance, advanced, annually, assist, awarded, bearing, borrowed, Bulletin, burn, carry, Code, compound, conditioned, consistent, consolidated, consulting, convertible, curve, cycle, decelerate, decreasing, delisted, delisting, delivery, depend, determining, disburse, dosing, efficacy, enhance, expanded, expended, experienced, filled, forfeited, hand, harmed, high, higher, implementing, income, incremental, industry, IPdR, issue, large, leading, leverage, licensor, limit, lump, material, maximum, organizational, owed, ownership, pace, payment, payroll, perform, pivotal, plain, potency, progression, prosecution, proven, public, pursued, qualify, receipt, recognize, relapsed, remain, rent, safety, sampling, simplified, spending, spent, sum, Talvesta, therapeutic, tolerability, toxicity, treasury, undertaken, updated, upfront, vanilla

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

TLON similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Hana Biosciences, Inc. does hereby certify that to the best of his knowledge:

(a) the Quarterly Report on Form 10-Q of Hana Biosciences, Inc. for the three months ended March 31, 2010 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(b) information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Hana Biosciences, Inc.

Dated: May 14, 2010	/s/ Steven R. Deitcher, MD
	Steven R. Deitcher, MD
	President and Chief Executive Officer

Dated: May 14, 2010	/s/ Craig W. Carlson
	Craig W. Carlson
	Vice President, Chief Financial Officer